An increasing number of oncology/hematology treatments will consist of oral oncolytics, and oncology programs are needed to manage the treatment of patients following these regimens.
The discovery of an enzyme that facilitates the spread of breast cancer may enable clinicians to prevent secondary cancer.
A combination approach utilizing three differing anticancer drug classes could hold the key to besting glioblastoma.
Drugs that are more commonly used to treat melanoma can also be use to help some individuals with lung cancer, research indicates.
Peripheral neuropathy associated with nab-paclitaxel among chemotherapy-naïve patients can be managed by dose interruptions and modifications.
A phase 3 trial of brentuximab vedotin (BV) showed that adults with hard-to-treat Hodgkin lymphoma given BV after stem cell transplantation survived without the disease progression for twice as long as when a placebo was administered.
Acute lymphoblastic leukemia (ALL) has been found to have two distinct subtypes, and evidence indicates that roughly 13% of ALL cases may be successfully treated with targeted drugs used in the treatment of lymphomas in adults.
Low doses of metformin and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors.
According to a new study, patients with diabetes become less adherent to their diabetes medication regimen following a diagnosis of cancer.
In treatment for metastatic breast cancer, eribulin is effective as a first-, second-, or third-line chemotherapy regimen.
How should a fibrin overgrowth on an internal catheter be managed when there is no blood return from the implanted port?
A drug used to treat Lou Gehrig's disease has also been found to improve the effectiveness of radiation therapy when administered to laboratory models with melanoma that metastasized to the brain.
Researchers have uncovered how melanoma becomes resistant to a promising new drug combination utilizing BRAF+MEK inhibitors after an initial period of tumor shrinkage.
Effectiveness of nanoparticle drugs was hindered by tumor microenvironment in triple-negative breast cancerJanuary 29, 2015
Nanoparticle drugs were considered to be a potential silver bullet against cancer, but they have not produced the anticipated improvement in overall survival rates.
Sunitinib, an agent approved for use in several cancers, could prove useful in treatment of thymic carcinoma when traditional chemotherapy fails.
Previously, patients with advanced colorectal cancer driven by a mutated version of the BRAF gene have had limited treatment options, but results from a multicenter clinical trial suggest a new option.
The current classification system for colorectal cancer, based on genetic profiles, cannot be used to predict drug responses to FOLFIRI.
What are the treatment options for recurrent metastatic HER2-positive breast cancer after trastuzumab therapy?
A PARP inhibitor in oral tablet form, given in combination with chemotherapy, was deemed safe for heavily pretreated patients with ovarian cancer.
A new use for an old drug shrinks a particular type of pancreatic cancer and stops it from spreading, according to new research.
New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs currently used to treat rheumatoid arthritis.
A gel containing the drug tamoxifen and applied to the skin was as effective as the pill form in reducing the growth of breast cancer cells in women with noninvasive cancer.
The addition of MM-398, a novel nanoliposome formulation of irinotecan, to standard treatment improves survival for metastatic pancreatic cancer patients who have already received gemcitabine.
A new combination of medications for treatment of recurrent ovarian cancer showed improved response rates, increased the rate of tumor shrinkage, and prolonged the time until cancers recurred
Nanomedicine technologies were utilized to develop a drug-delivery system that precisely targets and attacks cancer cells in the bone. It also increases bone strength and volume to prevent bone cancer progression.
A high-risk group of patients with follicular lymphoma could benefit from a novel drug combination, according to a new study published in the Journal of Experimental Medicine.
Five drug companies, the government, private foundations, and advocacy groups have come together to try a bold new way for testing cancer drugs. Described as a medical version of speed dating, physicians will sort through multiple experimental drugs and match patients to the one most likely to succeed.
Many older breast cancer patients with localized disease are taking drug treatments to prevent their cancer from returning, a new study finds. The research, covering a 7-year period, included more than 1,000 women, age 65 to 91 years, across the United States who had estrogen-positive breast cancer that had not spread.
Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.
A new study has discovered how resistance develops in patients taking ibrutinib, a new and highly effective drug for the treatment of chronic lymphocytic leukemia.
- In breast cancer survivors, lidocaine may relieve pain during intercourse
- Likelihood of lung cancer screening update
- Generic meds may boost survival in some early breast cancers
- Aromatase inhibitors substantially reduce risk of death in ER-positive breast cancer
- Activated T cell therapy developed for advanced melanoma
- St. John's wort: natural does not necessarily mean safe
- No association between opioids, breast cancer recurrence
- Researchers, providers need to address cancer health care disparities in LGBTQ community
- New combination could make cancer more sensitive to chemotherapy
- New approach to treating B-cell acute lymphoblastic leukemia shows promise
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|